Montelukast, a leukotriene receptor antagonist (LTRA), is a widely prescribed medication primarily used for the management of asthma and allergic rhinitis. Marketed under the brand name Singulair among others, it represents a cornerstone in the maintenance treatment of chronic respiratory conditions. This report details its mechanism of action, clinical applications, pharmacokinetics, safety considerations, and its place in current therapeutic guidelines.

1. Pharmacology and Mechanism of Action
Montelukast's therapeutic effect stems from its selective and competitive antagonism of the cysteinyl leukotriene type 1 receptor (CysLT1). Leukotrienes, particularly LTC4, LTD4, and LTE4, are potent inflammatory mediators derived from arachidonic acid via the 5-lipoxygenase pathway. In the airways, these eicosanoids cause bronchoconstriction, increased vascular permeability, mucus secretion, and eosinophil recruitment—key processes in the pathophysiology of asthma and allergic inflammation. By blocking the CysLT1 receptor, montelukast inhibits the action of these leukotrienes, leading to reduced bronchoconstriction and inflammation. It is important to note that it does not provide immediate relief of acute bronchospasm, as its action is prophylactic and anti-inflammatory rather than bronchodilatory.

2. Therapeutic Indications and Efficacy
The primary approved uses of montelukast are:
Chronic Asthma: It is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months and older. It is used as an add-on therapy for patients whose asthma is inadequately controlled on inhaled corticosteroids (ICS) or as an alternative controller medication for those with mild persistent asthma, particularly when adherence to inhalers is problematic. It is especially effective in exercise-induced bronchoconstriction (EIB) and in asthma exacerbated by aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
Allergic Rhinitis: Montelukast is approved for the relief of symptoms of seasonal allergic rhinitis (outdoor allergies) and perennial allergic rhinitis (indoor allergies) in adults and children aged two years and older. It helps alleviate symptoms such as sneezing, nasal congestion, runny nose, and itching.
Off-Label Uses: It is sometimes used off-label in conditions like chronic urticaria, atopic dermatitis, and obstructive sleep apnea, though evidence for these uses is less robust.

Clinical trials have consistently demonstrated montelukast's efficacy in improving asthma control, reducing exacerbation rates, and improving quality of life. Its oral formulation (chewable tablets, granules, and standard tablets) offers a significant advantage in pediatric populations and patients with poor inhaler technique.

3. Pharmacokinetics
Montelukast is rapidly absorbed after oral administration, with peak plasma concentrations achieved in 3 to 4 hours. The bioavailability is approximately 64% for the 10 mg film-coated tablet. It is highly bound (>99%) to plasma proteins. Montelukast is extensively metabolized in the liver by cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4. Its metabolites are excreted almost exclusively via the bile into the feces, with minimal renal excretion. The mean plasma half-life ranges from 2.7 to 5.5 hours in healthy adults. No significant dosage adjustments are typically required in elderly patients or those with renal impairment, but caution is advised in patients with hepatic insufficiency.

4. Dosage and Administration
Dosage is age-dependent:
Adults and adolescents (15 years and older): 10 mg once daily in the evening.
Children 6 to 14 years: 5 mg chewable tablet once daily in the evening.
Children 2 to 5 years: 4 mg chewable tablet or oral granules once daily in the evening.

• Children 12 to 23 months: 4 mg oral granules once daily in the evening.
  

For asthma, it should be taken daily for chronic therapy, regardless of the presence of symptoms. For allergic rhinitis, it can be taken daily as needed, depending on symptom duration. It may be taken with or without food, although administration with a high-fat meal can reduce bioavailability.

5. Safety Profile and Adverse Effects
Montelukast is generally well-tolerated. The most common adverse reactions in clinical trials were mild and included headache, ear infection, pharyngitis, upper respiratory infection, fever, cough, abdominal pain, diarrhea, and influenza. These were generally comparable to placebo.
However, montelukast carries a Boxed Warning—the FDA's strongest safety alert—regarding serious neuropsychiatric events. Post-marketing surveillance has reported cases of agitation, aggression, depression, sleep disturbances, suicidal ideation, and suicidal behavior. The risk appears to be higher in pediatric patients, though it can occur at any age. Patients and caregivers must be advised to monitor for changes in behavior or mood. The drug should be discontinued immediately if such symptoms occur.
Other important warnings include the potential for systemic eosinophilia (Churg-Strauss syndrome), which has been rarely reported, often in association with the reduction of oral corticosteroid therapy. It is not a teratogenic agent, but caution is advised during pregnancy (Pregnancy Category B).

6. Drug Interactions
Significant interactions are limited due to montelukast's low interference with major CYP enzymes. However, potent inducers of CYP enzymes (e.g., rifampicin, modaheal (corazondecarcar.es) phenobarbital, carbamazepine) can significantly reduce montelukast plasma concentrations, potentially diminishing its efficacy. Gemfibrozil, a CYP2C8 inhibitor, can increase montelukast exposure. Clinically significant interactions with commonly used asthma medications like theophylline, prednisone, or inhaled beta-agonists have not been observed.

7. Place in Therapy and Guidelines
According to major guidelines like the Global Initiative for Asthma (GINA), montelukast is considered a less preferred controller option compared to low-dose ICS for mild persistent asthma due to generally inferior efficacy in controlling inflammation and preventing severe exacerbations. Its primary role is as an add-on therapy to ICS, particularly when patients cannot or will not use inhaled combination therapies (ICS/LABA), or in specific phenotypes like aspirin-exacerbated respiratory disease (AERD) and EIB. Its ease of oral administration remains its most compelling practical advantage.

Conclusion
Montelukast is an effective and convenient oral anti-inflammatory agent that plays a specific and important role in the long-term management of asthma and allergic rhinitis. Its mechanism as a leukotriene receptor antagonist provides targeted inhibition of a key inflammatory pathway. While its safety profile is favorable for most patients, the boxed warning for neuropsychiatric events necessitates vigilant patient education and monitoring. Its use should be guided by a clear understanding of its strengths—particularly in specific asthma phenotypes and pediatric adherence—and its limitations compared to inhaled corticosteroid-based regimens.